[1] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10126):1301-1314.
|
[2] DURAND F,VALLA D. Assessment of prognosis of cirrhosis[J]. Semin Liver Dis,2008,28(1):110-122.
|
[3] PUGH RN,MURRAY-LYON IM,DAWSON JL,et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg,1973,60(8):646-649.
|
[4] JOHNSON PJ,BERHANE S,KAGEBAYASHI C,et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol,2015,33(6):550-558.
|
[5] KNOX JJ. Addressing the interplay of liver disease and hepatocellular carcinoma on patient survival:The ALBI scoring model[J]. J Clin Oncol,2015,33(6):529-531.
|
[6] TOYODA H,LAI PB,O’BEIRNE J,et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma:Application of the ALBI grade[J]. Br J Cancer,2016,114(7):744-750.
|
[7] WANG YY,ZHONG JH,SU ZY,et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg,2016,103(6):725-734.
|
[8] HIRAOKA A,KUMADA T,KUDO M,et al. Albumin-Bilirubin(ALBI)grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology:A comparison with the liver damage and child-pugh classifications[J]. Liver Cancer,2017,6(3):204-215.
|
[9] KAO WY,SU CW,CHIOU YY,et al. Hepatocellular carcinoma:Nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation[J]. Radiology,2017,285(2):670-680.
|
[10] PINATO DJ,SHARMA R,ALLARA E,et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma[J]. J Hepatol,2017,66(2):338-346.
|
[11] HEIMBACH JK,KULIK LM,FINN RS,et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology,2018,67(1):358-380.
|
[12] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
|
[13] LENCIONI R,de BAERE T,SOULEN MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data[J]. Hepatology,2016,64(1):106-116.
|
[14] SAPISOCHIN G,BARRY A,DOHERTY M,et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-totreat analysis[J]. J Hepatol,2017,67(1):92-99.
|
[15] VASNANI R,GINSBURG M,AHMED O,et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation[J]. Hepatobiliary Surg Nutr,2016,5(3):225-233.
|
[16] ZHAO Y,WANG WJ,GUAN S,et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma:A large-scale multicenter study of 222 patients[J]. Ann Oncol,2013,24(7):1786-1792.
|
[17] SIEGHART W,HUCKE F,PECK-RADOSAVLJEVIC M. Transarterial chemoembolization:Modalities,indication,and patient selection[J]. J Hepatol,2015,62(5):1187-1195.
|
[18] PINATO DJ,HOWELL J,RAMASWAMI R,et al. Review article:Delivering precision oncology in intermediate-stage liver cancer[J]. Aliment Pharmacol Ther,2017,45(12):1514-1523.
|
[19] BOLONDI L,BURROUGHS A,DUFOUR JF,et al. Heterogeneity of patients with intermediate(BCLC B)hepatocellular carcinoma:Proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis,2012,32(4):348-359.
|
[20] WANG Q,XIA D,BAI W,et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:A multicentre observational study[J]. J Hepatol,2019,70(5):893-903.
|